Late-breaking Phase III MASCOT oral presentation will characterize the clinical profile and diversity of participants in Lundbeck's ongoing global Phase ...
World MSA Day on October 3 highlights Multiple System Atrophy, a rare progressive neurological disorder affecting movement ...
Two devastating movement disorders, Parkinson’s disease and multiple system atrophy, often look so similar in the clinic that ...
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...
DelveInsight's "Multiple System Atrophy (MSA) Pipeline Analysis, 2020" highlights the details of the Multiple System Atrophy Pipeline Landscape Scenario, including disease overview, unmet needs, and ...
Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...
The growth of the MSA market is attributed to the increasing research and developmental activities to develop disease modifying therapies for MSA. For instance, in 2020, Neuraly raised $15 million in ...
There is currently no cure for the rare neurodegenerative disorder multiple system atrophy (MSA), and its rarity has made it difficult to understand how the disease progresses. Now a research team has ...
Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...
Wednesday, Tiziana Life Sciences ( TLSA) said it submitted a request to the FDA for Orphan Drug Designation for intranasal foralumab for the treatment of Multiple System Atrophy (MSA).
"On the day of the survey, my wife stood up from her chair and walked around the room a little. She didn't have any dizzy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results